Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
813.9 INR | +8.21% | +1.43% | +23.86% |
25/04 | Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024 | |
25/04 | Glenmark Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Sales 2024 | 22.83B 274M | Sales 2025 * | 25.79B 309M | Capitalization | 99.85B 1.2B |
---|---|---|---|---|---|
Net income 2024 | 4.71B 56.48M | Net income 2025 * | 5.5B 66.01M | EV / Sales 2024 | 4.17 x |
Net cash position 2024 * | 3.5B 41.96M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.87 x |
P/E ratio 2024 |
20.2
x | P/E ratio 2025 * |
18.2
x | Employees | 1,824 |
Yield 2024 * |
2.59% | Yield 2025 * |
2.95% | Free-Float | 15.72% |
Latest transcript on Glenmark Life Sciences Limited
1 day | +8.21% | ||
1 week | +1.43% | ||
Current month | +4.98% | ||
1 month | +4.99% | ||
3 months | -2.96% | ||
6 months | +30.39% | ||
Current year | +23.86% |
Managers | Title | Age | Since |
---|---|---|---|
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 13/19/13 |
Director of Finance/CFO | - | 01/22/01 | |
Compliance Officer | - | 23/21/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Manju Agarwal
BRD | Director/Board Member | 66 | 30/20/30 |
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 13/19/13 |
Sumantra Mitra
HRO | Human Resources Officer | 49 | 11/18/11 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 813.9 | +8.21% | 42,632 |
25/24/25 | 752.2 | -8.96% | 21,286 |
24/24/24 | 826.2 | -0.13% | 4,643 |
23/24/23 | 827.3 | -1.44% | 4,652 |
22/24/22 | 839.4 | +4.61% | 4,346 |
Delayed Quote Bombay S.E., April 26, 2024 at 03:41 pm IST
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- GLS Stock
- GLS Stock